injecting-2000x1350px-white

WE DEVELOP & DELIVER
VACCINES FOR GLOBAL
HEALTH
.

viles-2000x1333px-white

WE PARTNER GLOBALLY
TO FIGHT INFECTIOUS
DISEASE
.

ivi-hq-2000x1350px-white

WE ARE AN INTERNATIONAL
ORGANIZATION
BASED IN SEOUL,
SOUTH KOREA
.

Our Mission

IVI discovers, develops, and delivers safe, effective and affordable vaccines for global public health

Our Programs

IVI News and Announcements

favicon.png
Campaign to vaccinate about 27,000 people to prevent endemic cholera IVI Director General commends Rotary’s leadership and support, announces intent to provide additional vaccinations in developing countries through international collaboration The International Vaccine Institute (IVI), Rotary International (District 3640, District 3710), Rotary Club of Seoul Southwest in Korea, and Rotary Club of Nagarjun in Nepal announced on January 9 their global health partnership that recently completed vaccination of about 27,000 people at risk of cholera in Nepal. The vaccinations has been conducted in Banke, an area in southwest Nepal that borders with India, to protect people against cholera, a potentially fatal and highly contagious diarrheal disease. Cholera is endemic in Nepal, and people in the area are at high risk of cholera due to lack of clean water and limited sanitation and hygiene. The vaccination campaign used a two-dose oral cholera vaccine, developed by IVI through a public-private partnership with groups that include the Bill & Melinda Gates Foundation and the governments of Korea and Sweden. Notably, the vaccine ‘Euvichol’ is produced by the Korean vaccine manufacturer EuBiologics who worked with IVI on its development and production following technology transfer from IVI. The vaccine is prequalified by the World Health Organization and is the first Korean-made cholera vaccine for global public health. To ensure the vaccine reaches vulnerable populations, IVI collaborated with Rotary International and Nepalese health authorities to conduct the vaccination campaign, targeting residents one year old and up.  The first round occurred on early December, and the second round in mid- to late December. The vaccination campaign was led by Rotary Club of Seoul Southwest and International Rotary Districts 3640 and 3710, and was supported through a Global Grant from the Rotary Foundation. Collaborators in Nepal included the Nepalese Ministry of Health, Group for Technical Assistance (GTA), and other partners. The campaign was also supported by a number of Korean donors, including the Export Import Bank of Korea, the Kim & Chang CSR Committee, and Sartorius Korea Biotech. The campaign followed previous efforts by IVI to deliver cholera vaccines in Nepal, which has annual cholera outbreaks. The situation was exacerbated due to the earthquakes in 2015 that destroyed the health infrastructure in some remote parts of the country.  In 2015, the Institute conducted emergency vaccinations in Nuwakot and Dhading to contain sporadic cholera cases from spreading in the aftermath of the earthquakes. IVI Director General Dr. Jerome Kim said, “Through a collaboration with Rotary and with support from donors, we were able to provide much-needed protection to people in cholera-prone areas in Nepal,” adding, “We hope this project will be the starting point to expand our partnership with Rotary International who successfully spearheaded the Global Polio Eradication Initiative with other partners.” “Thanks to great support from our donors in Korea and elsewhere, we have been able to deliver vaccines to needy populations at risk of cholera,” Dr. Kim said, “We hope to see continued support from companies and donors in Korea so that we can protect more people against cholera.” IVI, Korea Support Committee for IVI, and Rotary District 3640 exchanged a three-way memorandum of understanding in September this year with the view to conducting joint vaccination projects to prevent cholera among children in developing countries.       ###   About IVI The International Vaccine Institute (IVI) is the world’s only international organization devoted exclusively to developing and introducing new and improved vaccines to protect the world’s poorest people, especially children in developing countries. Established in 1997, IVI operates as an independent international organization under a treaty signed by 35 countries and the World Health Organization. The Institute conducts research in more than 20 countries of Asia, Africa and Latin America on vaccines against enteric and diarrheal infections, Japanese encephalitis, MERS-CoV, and dengue fever, and develops new and improved vaccines at its headquarters in Seoul, Republic of Korea. For more information, please visit http://www.ivi.int.
favicon.png
- IVI to serve as local host and co-sponsor The U.S.-Japan Cooperative Medical Sciences Program’s 19th International Conference on Emerging Infectious Diseases (EID) and associated Workshop on Cholera and Other Bacterial Enteric Infections will be on February 7-10, 2017 at the Novotel Seoul Ambassador Gangnam Hotel. Organized by the U.S. National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH), the Japanese Ministries of Health, Labor and Welfare (MHLW) and Education, Culture, Sports, Science and Technology (MEXT), and the Japan Agency for Medical Research and Development (AMED), IVI is the local host of this year’s conference. Since 1996, the United States-Japan Cooperative Medical Sciences Program has been convening the EID conference annually in alternating countries. It serves as a venue for panel meetings and discussion of cross-cutting topics related to infectious disease research to promote international cooperation in research efforts in response to new, emerging infectious disease challenges of Asia and the greater Pacific region. Participants include researchers, government and public health officials, and representatives from academia and other public and private institutions from countries within the Pacific Rim region, including Korea, Japan, and the United States. For more information about EID and the Workshop, please visit: https://respond.niaid.nih.gov/conferences/USJapanCMSP2017/Pages/default.aspx https://respond.niaid.nih.gov/conferences/usjapancmsp/Pages/Cholera-Panel.aspx Planning is in process and more information about the conference will be provided shortly.
forum_3.jpg
International meeting convenes leading scientists and experts to accelerate development of vaccines against group A Streptococcus (GAS) GAS is a potentially deadly bacterial pathogen, causing rheumatic heart disease and invasive infection in developing countries December 13, 2016, Seoul, Korea – The International Vaccine Institute (IVI) and the World Health Organization (WHO) are co-hosting the Global Stakeholder Consultation on Group A Streptococcal (GAS) Vaccine Development at the Sheraton Seoul Palace Gangnam Hotel from December 12-13. The one-and-a-half-day meeting convenes international scientific experts, vaccine developers and funders to review evidence on GAS burden of disease and the need for a vaccine, and to discuss the feasibility and pathway for developing GAS vaccines.  The meeting is in line with WHO’s goal to accelerate the development and licensure of high-quality, safe and effective GAS vaccines for low-and middle-income countries. Group A Streptococcus (Streptococcus pyogenes) is a bacterial pathogen that causes a broad spectrum of disease ranging from mild infections such as strep throat that lead to progressive heart damage and death. The disease is often associated with lower development status and poverty, and is commonly found in Africa, the Subcontinent, the islands of the Pacific, and among the First Nations of Canada, the native peoples of Australia and New Zealand, and native Americans. The WHO estimates GAS causes a substantial burden of disease and death globally, especially in low and middle-income countries where rheumatic heart disease and invasive infections are common. Globally over 400,000 people die every year from complications of infection. A vaccine is currently not available. Speakers and participants include representatives from organizations such as PATH, Wellcome Trust, Prevent Canada, US Centers for Disease Control and Prevention, GSK, Pfizer, Sanofi, London School of Hygiene & Tropical Medicine, University of Auckland, Murdoch Children’s Research Institute, University of Queensland, University of Melbourne, and University of Hawaii among others. Her Excellency Clare Fearnley, the New Zealand Ambassador to Korea, and Mr. Ravi Kewalram, Chargé d'Affaires of the Australian Embassy Seoul gave opening remarks on the first day. The meeting is supported by Shinil, the Coalition to Advance New Vaccines against group A Streptococcus (CANVAS), RHD Action, and the Murdoch Children’s Research Institute.  It is also the second in a series of annual global vaccine fora organized by IVI and supported by Shinil. “The consultation provides an excellent opportunity to discuss, coordinate and mobilize resources and action at a global level to take concerted action against group A Streptococcus,” said Jerome Kim, IVI Director General, “The increasing body of evidence shows that the burden of GAS diseases and its linkage with poverty cannot be ignored. The global health community must work together to accelerate the development of a vaccine against this major killer.” ###   About IVI The International Vaccine Institute (IVI) is the world’s only international organization devoted exclusively to developing and introducing new and improved vaccines to protect the world’s poorest people, especially children in developing countries. Established in 1997, IVI operates as an independent international organization under a treaty signed by 35 countries and the World Health Organization. The Institute conducts research in more than 20 countries of Asia, Africa and Latin America on vaccines against enteric and diarrheal infections, Japanese encephalitis, MERS-CoV, and dengue fever, and develops new and improved vaccines at its headquarters in Seoul, Republic of Korea. For more information, please visit http://www.ivi.int. Media Contact: IVI Tae Kyung Byun Phone: +82-2-872-2801 (Ext. 159) Mobile: +82-11-9773-6071 Email: tkbyun@ivi.int

On the blog

An IVI Blog will be launched soon…

Our Donors

Stay Connected